Human Relevant Data & Biosignatures
Farcast's extensively published models ensure that tissue fragments are optimally sized, maintaining the equilibrium between stromal, tumor and immune components and retaining the spatial contexture of the original tumor microenvironment. Such living, near native, heterogeneous tumor systems are ideal for determining true treatment impact and predicting tumor and immune responses
​
Farcast's technology comprehensively combines multimodal data from every tumor processed with available multiomics and clinical information. The AI (artificial intelligence) enabled technology computes response biosignatures of treatments with higher precision that truly elucidate the complexities of tumor responses
​​
Application of such true perturbation based human biosignatures leads to a much more precise identification of responder phenotypes than traditional biomarkers or baseline signatures
​
Test Combination Therapies
Develop combination strategy and test synergy with existing treatments
Scout New Indications
Expand the range of indications of your pipeline
Evaluate Mechanism of Action
Gain confidence in the mechanism of your therapeutic candidate
Discover Predictive Biosignatures
Optimal patient stratification for enhanced response rates
HISTOPATHOLOGY
Morphological assessment of mechanistic response of drug to assess proliferation, cell death and immune cell infiltration induced by treatment
GENE EXPRESSION
Measurement of differential gene expression resulting from therapeutic intervention
Patient cohort stratification discovery with baseline gene expression
​
​
(Opal690)%2C%20CD8(Opal570)%2C%20CD4(Opal520)%2C%20panCK(AF750)-image-6_j.jpeg)
Farcast proprietary images
PanCK
Fox P3
CD8
SPATIAL BIOLOGY
Live imaging that offers a comprehensive evaluation of true tumor microenvironment
​
Multiplex immunofluorescence techniques that help visualization of the spatial distribution of different sub-population of immune and cancer cells in the original human tumor microenvironment
​
Assessment of changes in spatial biology caused by therapeutic intervention in the treated tumor microenvironment
​
​
​
FLOWCYTOMETRY
Precise measurement and characterization of diverse immune cell populations within the tumor microenvironment
Customized panels for assessment of specific immune cell type activity indicative of therapy response
CYTOKINE PROFILING
Flexible, multiplexed quantitative evaluation of cytokines/chemokines released due to therapeutic intervention
Immune effector cells for assessing early response in tumor fragments in response to drug exposure
KINETIC ASSAYS
Discrete time course measurements to understand the metabolic state and viability of explants in the culture system for up to 72 hours
